Equities research analysts expect Bicycle Therapeutics Limited (NASDAQ:BCYC) to report $800,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Bicycle Therapeutics’ earnings. The highest sales estimate is $1.00 million and the lowest is $600,000.00. The firm is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Bicycle Therapeutics will report full year sales of $8.84 million for the current fiscal year, with estimates ranging from $7.90 million to $9.52 million. For the next fiscal year, analysts anticipate that the company will report sales of $4.20 million, with estimates ranging from $3.40 million to $5.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, November 7th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.05. Bicycle Therapeutics had a negative return on equity of 238.49% and a negative net margin of 342.94%. The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $1.00 million.

A number of brokerages have recently commented on BCYC. Canaccord Genuity set a $22.00 price target on Bicycle Therapeutics and gave the company a “buy” rating in a report on Monday, September 30th. Goldman Sachs Group raised shares of Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, September 11th. Roth Capital assumed coverage on shares of Bicycle Therapeutics in a research report on Thursday, November 14th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Zacks Investment Research raised shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Bicycle Therapeutics has an average rating of “Buy” and an average target price of $19.00.

A number of large investors have recently made changes to their positions in BCYC. Monashee Investment Management LLC acquired a new stake in Bicycle Therapeutics in the second quarter worth approximately $532,000. Pentwater Capital Management LP bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $642,000. Laurion Capital Management LP bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $1,006,000. Victory Capital Management Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $1,403,000. Finally, Atlas Venture Advisors Inc. acquired a new position in shares of Bicycle Therapeutics during the 2nd quarter valued at $13,709,000. 36.27% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:BCYC traded down $0.31 on Friday, hitting $8.30. The company’s stock had a trading volume of 12,584 shares, compared to its average volume of 13,177. Bicycle Therapeutics has a 12 month low of $6.24 and a 12 month high of $14.91. The company’s 50-day moving average price is $9.10.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Featured Article: Inverted Yield Curve

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.